Nexign Completed Migration of Subscribers in All Yota’s Branch Offices
7.10.2020 09:00:00 EEST | Business Wire | Press release
Nexign (a part of ICS Holding LLC), a leading Business Support System (BSS) and Internet of Things (IoT) solutions provider, today announced the successful migration of subscribers in all branch offices of the Russian mobile broadband services provider Yota to the Nexign Network Monetisation Suite – a versatile solution for real-time rating, charging and policy control across all network services.
Yota was the first operator to offer its customers communication bundles configurable to minutes and gigabytes, as well as differentiated payment for various types of traffic. Yota’s existing solution did not enable horizontal scaling. The company needed a scalable and flexible instrument for charging and policy control inside the network.
To increase effectiveness of its internal processes, Yota opted for Nexign Network Monetisation Suite, which included solutions like PCRF (Policy and Charging Rules Function), RCAF (RAN congestion awareness function) and UDR (User Data Repository).
As a result, Yota received future-proof solution, which fully met the needs of the mobile operator. Yota reduced the total cost of ownership (TCO) by 10-20% by saving on additional third-party licenses. Use of PCRF function enabled the company to reduce time to market (TTM) by 20% and increase the fault tolerance by 40%, which allows the operator to deliver great customer service and stand out from competition. Nexign’s solution helps Yota provide customer services even in the conditions of congestion.
“The jointed project with Nexign allowed us to launch unique product for the telco market called 'The communications constructor' and maintain high quality of our services while increasing the number of customers. In the past six months the new solution underwent unprecedented stress test. Due to the pandemic, traffic from business apps inside the network has grown 2.5 times,” said Andrey Zhikin, IT Director of Yota.
“This project is the first time when Nexign implemented its solution in a telecom operator that uses a third-party billing system,” said Alexey Vedin, Director of Network Monetisation Products at Nexign. “Integration with Yota’s BSS systems was carried out with no impact on Yota’s customers and without any failures or service interruption. No additional modifications were required on the part of billing or other systems – all the needs of the operator were covered by the capabilities of Nexign’s solution.”
Learn more about Nexign’s products and services here: https://nexign.com/en.
About Nexign
Nexign, a part of Intellectual Computer Systems Holding (https://x-holding.ru/) and a leading Business Support System (BSS) and Internet of Things (IoT) solutions provider, has been delivering pragmatic, value-driven, high-performance product solutions since 1992. Nexign has an experience of transformational projects of all scales, and a proven track record of achieving revenue boosts for CSPs through systems consolidation and a faster go-to-market time for new services after modernisation.
Headquartered in St. Petersburg, Nexign employs 1,800 people in offices through Russia, the CIS, the Middle East, Africa, Southeast Asia and LATAM. For more information, please visit the website and follow Nexign on Twitter, Facebook and LinkedIn.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201006006022/en/
Contact information
Alena Semenova
Alena.Semenova@nexign.com
+79117237518
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release
International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom